Top

Supportive Care in Cancer

Published in:

01-03-2021 | Nausea | Original Article

Creation of a chemotherapy-induced nausea/vomiting dashboard to improve outcomes for pediatric cancer patients

Authors: Alexandra M. Walsh, Jennifer Hess, Melissa Rees, Cynthia Wetmore, Vinay Vadiya

Published in: Supportive Care in Cancer | Issue 3/2021

Abstract

Purpose

Two of the most common acute side effects of chemotherapy are nausea and vomiting. Nausea and vomiting impact quality of life, nutritional status, and ability to tolerate further chemotherapy. Parents of pediatric oncology patients rank nausea as one of the most bothersome treatment-related symptoms.

Methods

Utilizing Quality Improvement methodology, we developed a dashboard interface to facilitate extraction of data from the electronic medical record (EMR), which is presented via a visual display that summarizes the type of chemotherapy and antiemetic medications, use of as needed medications, and number of episodes of emesis.

Results

This dashboard interface allows for rapid and efficient identification of patients whose antiemetic regimen is mismatched for the emetogenicity of ordered chemotherapy, thus providing a timely opportunity to modify the antiemetic regimen based on published guidelines before administration of chemotherapy drugs. It also allows measurement of the effectiveness of the antiemetic regimen in terms of the number of break through emesis and the need for as needed medications.

Conclusions

A novel CINV dashboard was created, which visually conveys complex information about antiemetics, chemotherapy emetogenicity, as needed medications, and breakthrough vomiting for inpatient pediatric oncology patients.

National Cancer Institute: Surveillance, epidemiology, and end results Program, SEER Cancer Review Statistics. (1975-2015). https://seer.cancer.gov/csr/1975_2015/browse_csr.php?sectionSEL=28&pageSEL=sect_28_table.08. Accessed November 20 2019

Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065–2071. https://doi.org/10.1016/j.bbmt.2018.06.005CrossRefPubMed

Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J 43(1):73–76. https://doi.org/10.1111/j.1445-5994.2011.02637.xCrossRefPubMed

Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, O'Shaughnessy E, Sung L, Pediatric Oncology Group of O (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60(7):1073–1082. https://doi.org/10.1002/pbc.24508CrossRefPubMed

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25(7):1328–1333. https://doi.org/10.1093/annonc/mdu101CrossRefPubMedPubMedCentral

Affronti ML, Schneider SM, Herndon JE, Schlundt S, Friedman HS (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 22(7):1897–1905. https://doi.org/10.1007/s00520-014-2136-0CrossRefPubMedPubMedCentral

Dupuis LL, Milne-Wren C, Cassidy M, Barrera M, Portwine C, Johnston DL, Silva MP, Sibbald C, Leaker M, Routh S, Sung L (2010) Symptom assessment in children receiving cancer therapy: the parents' perspective. Support Care Cancer 18(3):281–299. https://doi.org/10.1007/s00520-009-0651-1CrossRefPubMed

McKinnon K, Jupp J, Ghosh S, Digout C, Eason S, Romanick M (2018) Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. Pediatr Blood Cancer:e27488. https://doi.org/10.1002/pbc.27488

Polito S, MacDonald T, Romanick M, Jupp J, Wiernikowski J, Vennettilli A, Khanna M, Patel P, Ning W, Sung L, Dupuis LL (2018) Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: a multicenter, retrospective review. Pediatr Blood Cancer 65(12):e27374. https://doi.org/10.1002/pbc.27374CrossRefPubMed

10.

Medicine IIo (2011) Clinical practice guidelines we can trust: committee on standards for developing trustworthy clinical practice guidelines. The National Academies Press, Washington DC

11.

Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L (2006) Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy 26(9):1221–1231. https://doi.org/10.1592/phco.26.9.1221CrossRefPubMed

12.

Dupuis LL, Sung L, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25(1):323–331. https://doi.org/10.1007/s00520-016-3384-yCrossRefPubMed

13.

Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, Holdsworth M, Ontario POGo (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57(2):191–198. https://doi.org/10.1002/pbc.23114CrossRefPubMed

14.

Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ (2017) 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 25(1):271–275. https://doi.org/10.1007/s00520-016-3332-xCrossRefPubMed

15.

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, investigators P (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. https://doi.org/10.1093/annonc/mds021CrossRefPubMed

16.

Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A (2017) 2016 updated MASCC/ESMO consensus recommendations: anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer 25(1):317–321. https://doi.org/10.1007/s00520-016-3330-zCrossRefPubMed

17.

Carroll C, Clinton F, Smith A, Fox A, Capra M, Pears J, Owens C (2018) Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma. Pediatr Blood Cancer 65(12):e27386. https://doi.org/10.1002/pbc.27386CrossRefPubMed

18.

Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202. https://doi.org/10.1016/j.ejphar.2013.09.073CrossRefPubMed

19.

Patel P, Robinson PD, Orsey A, Freedman JL, Langevin AM, Woods D, Sung L, Dupuis LL (2016) Chemotherapy-induced nausea and vomiting prophylaxis: practice within the Children's oncology group. Pediatr Blood Cancer 63(5):887–892. https://doi.org/10.1002/pbc.25915CrossRefPubMedPubMedCentral

20.

Weggelaar-Jansen AMJW, Broekharst DSE, de Bruijne M (2018) Developing a hospital-wide quality and safety dashboard: a qualitative research study. BMJ Qual Saf 27:1000–1007. https://doi.org/10.1136/bmjqs-2018-007784CrossRefPubMedPubMedCentral

21.

Martinez DA, Kane EM, Jalalpour M, Scheulen J, Rupani H, Toteja R, Barbara C, Bush B, Levin SR (2018) An electronic dashboard to monitor patient flow at the Johns Hopkins Hospital: communication of key performance indicators using the Donabedian model. J Med Syst 42(8):133. https://doi.org/10.1007/s10916-018-0988-4CrossRefPubMed

22.

Battjes R, Jones L, Groves C, Fakih M (2017) An innovative approach to evaluate hospital and system improvements in infection prevention: development of a dynamic bacteremia dashboard. Am J Infect Control 45(6):S46CrossRef

23.

Lee K, Jung SY, Hwang H, Yoo S, Baek HY, Baek RM, Kim S (2017) A novel concept for integrating and delivering health information using a comprehensive digital dashboard: an analysis of healthcare professionals' intention to adopt a new system and the trend of its real usage. Int J Med Inform 97:98–108. https://doi.org/10.1016/j.ijmedinf.2016.10.001CrossRefPubMed

24.

Shaw SJ, Jacobs B, Stockwell DC, Futterman C, Spaeder MC (2015) Effect of a real-time pediatric ICU safety bundle dashboard on quality improvement measures. Jt Comm J Qual Patient Saf 41(9):414–420PubMed

25.

Hagland M (2010) First place. Children's Hospital of Pittsburgh. Improving patient care through data availability in the ICU. Healthc inform 27(3):20–21 23, 26 passimPubMed

26.

Badgeley MA, Shameer K, Glicksberg BS, Tomlinson MS, Levin MA, McCormick PJ, Kasarskis A, Reich DL, Dudley JT (2016) EHDViz: clinical dashboard development using open-source technologies. BMJ Open 6(3):e010579. https://doi.org/10.1136/bmjopen-2015-010579CrossRefPubMedPubMedCentral

27.

Shailam R, Botwin A, Stout M, Gee MS (2018) Real-time electronic dashboard technology and its use to improve pediatric radiology workflow. Curr Probl Diagn Radiol 47(1):3–5. https://doi.org/10.1067/j.cpradiol.2017.03.002CrossRefPubMed

28.

Fox LA, Walsh KE, Schainker EG (2016) The creation of a pediatric hospital medicine dashboard: performance assessment for improvement. Hosp Pediatr 6(7):412–419. https://doi.org/10.1542/hpeds.2015-0222CrossRefPubMed

29.

Itri JN, Bakow E, Probyn L, Kadom N, Duong PT, Gettle LM, Mendiratta-Lala M, Scali EP, Winokur RS, Zygmont ME, Kung JW, Rosenkrantz AB (2017) The science of quality improvement. Acad Radiol 24(3):253–262. https://doi.org/10.1016/j.acra.2016.05.010CrossRefPubMed

30.

Portela MC, Pronovost PJ, Woodcock T, Carter P, Dixon-Woods M (2015) How to study improvement interventions: a brief overview of possible study types. BMJ Qual Saf 24(5):325–336. https://doi.org/10.1136/bmjqs-2014-003620CrossRefPubMedPubMedCentral

31.

Green LW, Ottoson JM, García C, Hiatt RA (2009) Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health 30:151–174. https://doi.org/10.1146/annurev.publhealth.031308.100049CrossRefPubMed

32.

Bresnick J (2018) EHR, Lab Data Support Pediatric AKI Analytics Dashboard. https://healthitanalytics.com/news/ehr-lab-data-support-pediatric-aki-analytics-dashboard. Accessed 20 July 2020

33.

Flank J, Nadeem K, Moledina S, Khanna M, Schindera C, Punnett A, Dupuis LL (2017) Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: a prospective, observational study. Pediatr Blood Cancer 64(10). https://doi.org/10.1002/pbc.26603

Title: Creation of a chemotherapy-induced nausea/vomiting dashboard to improve outcomes for pediatric cancer patients
Authors: Alexandra M. Walsh
Jennifer Hess
Melissa Rees
Cynthia Wetmore
Vinay Vadiya
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keywords: Nausea
Vomiting
Cytostatic Therapy
Pediatric Cancer
Published in: Supportive Care in Cancer / Issue 3/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05652-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

The effect of chemotherapy on olfactory function and mucociliary clearance

Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic

The association of health status and cancer history of young adult survivors of childhood cancer with parental accompaniment to survivorship clinic visits

Exploring the dietary choices of Chinese women living with breast cancer in Vancouver, Canada

Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study

Demand for weekend outpatient chemotherapy among patients with cancer in Japan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer